Sign in
CompletedPhase 2

Tocilizumab in Active Moderate-severe Graves' Orbitopathy

Key facts

Who runs it
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Where
Italy4 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
56 people enrolled
Started
18 Dec 2019
Ended
18 Mar 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Tocilizumab 20 Mg/mL Intravenous Solution
  • MethylPREDNISolone Injectable Solution
Record updated
23 October 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 54 criteriaShow less

Who can take part

  • Written informed consent
  • Male or female, 18-75 years old
  • Women of childbearing potential should use effective contraception (abstinence or use contraceptive methods with a failure rate of <1%) throughout study and for a minimum of 6 months after study drug therapy and must have a negative serum pregnancy test at screening
  • GO at first diagnosis or at the time of relapse of no more than 9 months' duration
  • Patients with moderate-severe active GO (clinical activity score 4/10 assessed at the end of the screening period) untreated or previously treated with i.v. steroids withdrawn for at least 3 months
  • Euthyroid for at least 6-8 weeks (serum free hormone concentrations within 20% of normal range), on either anti-thyroid medications (tyonamides) to control hyperthyroidism or L-thyroxine for replacement therapy for hypothyroidism
  • Patients will also be allowed to stay on propranolol treatment for the control of tachycardia

Who cannot take part

  • Treatment with any biological therapy at any time
  • Previous oral or intravenous corticosteroid treatment in the last three months except for oral steroid not exceeding a cumulative dose of 1 gr
  • Plasmapheresis within 90 days prior to Day 0
  • Treatment with intravenous immunoglobulin
  • Azathioprine more than 100 mg/day within 30 days before screening
  • Administration of live vaccines given within 30 days prior to administration of (Day 0) or concurrently with tocilizumab (during study)
  • Required management of infections, as follows: currently on any suppressive therapy for a chronic infection, hospitalization for treatment of infection within 60 days before Day 0, use of parenteral antibiotics within 60 days before Day 0, use of oral antibiotics within 30 days before Day 0
  • Patients with reproductive potential not willing to use an effective method of contraception throughout study and for a minimum of 6 months after study drug therapy
  • Previous history of intestinal ulceration or diverticulitis or diverticular disease
  • Previous orbital radiotherapy
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy including a previous anaphylactic reaction to parenteral administration contrast agents, human or murine proteins or monoclonal antibodies
  • Current drug or alcohol abuse or dependence
  • Treatment with Methotrexate
  • Subjects at risk of bleeding that threatens a vital organ
  • History of a major organ transplant or hematopoietic stem cell/marrow transplant
  • History of malignant neoplasm within the last 5 years, except for adequately treated cancers of the skin (basal or squamous cell) or carcinoma in situ of the uterine cervix
  • Known unstable coronary artery disease
  • Significant cardiac arrhythmias
  • Severe congestive heart failure
  • Other serious chronic illness (including nervous system disease, pulmonary disease including obstructive pulmonary disease, renal disease)
  • Active infection
  • History of recurrent clinically significant infection or recurrent bacterial infections
  • History of sarcoidosis
  • History of IgE-mediated or non-IgE-mediated hypersensitivity
  • Positive PPD or quantiferon without documentation of treatment for TB infection
  • Denied consent to HIV testing
  • HBcAb positive test, regardless of HBsAb status, will undergo HBV DNA which, if positive, will be excluded
  • Hepatitis C antibody positive test at screening
  • Positive test for Human Immunodeficiency Virus (HIV) antibody at screening or historically
  • Evidence of serious suicide risk including any history of suicidal behaviour in the last 6 months and/or any suicidal ideation in the last 2 months or who in the investigator's judgment, pose a significant suicide risk
  • Demyelinating disorders
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) greater or equal to 1.5x upper limit of normal (ULN)
  • Alkaline phosphatase and bilirubin>1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin is<35%)
  • White blood cells < 3.0 x 109/L (3000/mm3)
  • Absolute neutrophil count (ANC) < 2.0 x 109/L (2000/ mm3)
  • Absolute lymphocyte count < 0.5 x 109/L (500/ mm3)
  • Platelet count <100 x 109/L
  • Serum creatinine > 1.4 mg/dl (124 µmol/L) in female patients and > 1.6 mg/dl (141 µmol/L) in male patients
  • Hemoglobin <85 g/L (8.5 g/dL; 5.3 mmol/L)
  • Patients with sight-threatening Graves' orbitopathy (severe keratopathy, compression optic neuropathy and inflammatory optic neuropathy)
  • Splenectomy
  • Pregnancy
  • Breast feeding
  • Primary or secondary immunodeficiency
  • HBsAg positive test
  • Grade 3 / 4 IgG deficiency and IgA deficiency (IgA < 10mg/dL)
  • Major depression

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To treat patientis with active moderate-severe GO with the anti-IL6 receptor monoclonal antibody tocilizubam with the purpose of assesing the efficacy of therapy on active GO and on the proportion of patiens with inactivation and reactivation of disease (Primary Objective) Effect of therapy on disease progression, improvement of QoL, the degree of residual disease after the inflammatory phase and safety of treatment (Secondary Objective)

The 2 groups in the trial

  • TocilizumabTreatment being tested

    32 patients with active moderate-severe GO treated with i.v. tocilizumab; Tocilizumab weight adjusted, 8 mg/kg, 1 intravenous infusion every four weeks (+/- 72 hours) for 12 weeks

    Treatment: Tocilizumab 20 Mg/mL Intravenous Solution

  • MethylprednisoloneExisting treatment, for comparison

    32 patients with active moderate-severe GO treated with i.v. methylprednisolone; Methylprednisolone, 500 mg infusion weekly (+/- 48 hours) for 6 weeks, followed by 250 mg infusion weekly (+/- 48 hours) for another 6 weeks

    Treatment: MethylPREDNISolone Injectable Solution

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Multicenter, Randomized, Observer-blind, Controlled Study of the Anti-IL-6 Receptor Antibody Tocilizumab (TCZ) or Methylprednisolone (MP) Treatment in Patients With Active Moderate-severe Graves' Orbitopathy
Record updated
23 October 2026